First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 987-993

  Liang, X ^a   Yan, Ying ^a   Wang, Lina ^a   Song, Guohong ^a   Di, Lijun ^a   Jiang, Hanfang ^a   Wang, Chaoying ^a   Li, Huiping ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Capecitabine; Docetaxel; Maintenance therapy; Metastatic breast cancer

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; PYRIDOXINE; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84918769522     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2787     Document Type: Article

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Thun MJ, Jemal A and Ward E: Global cancer incidence and mortality. In: Cancer: Principles and Practice of Oncology. DeVita VT Jr (ed). 9th edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp241-266, 2011.
3. Gennari A, Amadori D, De Lena M, et al: Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24: 3912-3918, 2006.
4. Alba E, Ruiz-Borrego M, Margelí M, et al: Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 122: 169-176, 2010.
5. Gennari A, Stockler M, Puntoni M, et al: Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29: 2144-2149, 2011.
6. Dufresne A, Pivot X, Tournigand C, et al: Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci 5: 100-105, 2008.
7. Bertelli G, Garrone O, Bertolotti L, et al: Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 68: 364-370, 2005.
8. Mayer IA: Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer 9 (Suppl 2): S50-S57, 2009.
9. Leonard R, Hennessy BT, Blum JL and O'Shaughnessy J: Dose-adjusting capecitabine minimizes side effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 11: 349-356, 2011.
10. Górnaś M and Szczylik C: Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process? Eur J Cancer Care (Engl) 19: 131-136, 2010.
11. ®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233, 2003.
12. Kusama M, Nomizu T, Aogi K, et al: Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17: 233-240, 2010.
13. Hortobagyi GN, Gomez HL, Li RK, et al: Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 122: 409-418, 2010.
14. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
15. Blum JL, Dees EC, Vukelja SJ, et al: Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 7: 465-470, 2007.
16. Chan A and Verrill M: Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer 45: 2253-2265, 2009.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
19. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
20. Nicolini A, Giardino R, Carpi A, et al: Metastatic breast cancer: an updating. Biomed Pharmacother 60: 548-556, 2006.
21. Cardoso F, Bedard PL, Winer EP, et al; ESO-MBC Task Force: International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst 101: 1174-1181, 2009.
22. Park YH, Jung KH, Im SA, et al: Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 31: 1732-1739, 2013.
23. Martín M and López-Tarruella S: Chemotherapy: Maintenance therapy in breast cancer - many questions remain. Nat Rev Clin Oncol 10: 370-372, 2013.
24. Sledge GW Jr, Hu P, Falkson G, Tormey D and Abeloff M: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18: 262-266, 2000.
25. Beaver JA and Park BH: The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 8: 651-657, 2012.
26. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002.
27. Burstein HJ: Novel agents and future directions for refractory breast cancer. Semin Oncol 38 (Suppl 2): S17-S24, 2011.
28. Mouridsen H, Sun Y, Gershanovich M, et al: Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9: 489-496, 2004.
29. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a north american multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767, 2000.
30. Mauri D, Pavlidis N, Polyzos NP and Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98: 1285-1291, 2006.
31. Falkson G, Gelman RS, Pandya KJ, et al: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669-1676, 1998.
32. Nooij MA, de Haes JC, Beex LV, et al; EORTC Breast Cancer Group: Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists' preferences. Eur J Cancer 39: 614-621, 2003.